2025 Beacon Meeting Archive

Posted on December 31, 2025 by Beacon Angels

The regular meetings of Beacon Angels in 2025 covered the following:

January 14, 2025

Care Hero & Abyiss

Beacon Angels members conducted the following new business at its meeting on Tuesday, January 14, 2025:

We entertained new funding proposals from the following:

  • Care Hero, developing an online marketplace to help families find, hire, and manage vetted in-home caregivers for seniors aging in place.
  • Abyiss, developing crypto on & off ramping–connecting bank accounts to digital wallets to enable seamless crypto-to-cash conversions.

We heard an update from:

  • NF2 Therapeutics on progress towards the treatment and cure of the NF2 orphan genetic disease both (a) in vitro and in vivo through the development of antibody–drug conjugates or ADC candidates for treatment, and (b) with its proof-of-concept studies towards a gene therapy cure.

We considered multiple funding rounds, by Series number:

  • S134 – eCareVault
  • S136 – NIRA
  • S137 – LenossMedical
  • S139 – Neosoma

Members reported on companies in due diligence:

  • AsqMe,“ZenDesk for the Creator Economy”.
  • iQ3Connect, offering 3D interactive hands-on learning accessible at scale on any device in a web browser.

February 11, 2025

Anvil Diagnostics & IRIS Therapeutic Devices

Beacon Angels members conducted the following new business at its meeting on Tuesday, February 11, 2025:

We entertained new funding proposals from the following:

  • AnvilDiagnostics – building a routine blood test to screen for hundreds of pathogen genes in high-risk cancer patients.
  • IRIS TherapeuticDevices – developing and commercializing a device to reverse the effects of Parkinson’s disease.

We heard updates from the Beacon portfolio companies,

  • Lenoss Medical – provided an update on its significant progress towards the treatment of spinal fractures with the OsteoPearl VBA System – a minimally invasive and cement-free technology that utilizes the natural healing properties of healthy bone.
  • GelMEDIX – updated us on progress delivering ocular cell therapy solutions to improve cell viability, engraftment, and tissue regeneration to restore vision.

We considered multiple funding rounds, by Series number:

  • S96C – NF2Therapeutics, Inc.
  • S136 – NIRA
  • S137 – LenossMedical
  • S139 – Neosoma
  • S131 – PykusTherapeutics
  • [S140] – AILean
  • [S141 – GelMEDIX

Members reported on companies in due diligence:

  • AsqMe, “ZenDesk for the Creator Economy” (pass)
  • iQ3 Connect, offering 3D interactive hands-on learning accessible at scale on any device in a web browser (positive).

March 11, 2025

Alpha Cure Therapeutics, MantaBio & Joined Bio

At the Beacon Angels meeting on Tuesday, March 11, 2025, we entertained new funding presentations as follows:

  • AlphaCureTherapeutics, developing precision safe radioligand therapy via small molecule next-generation BNCT, initially focused on Triple Negative Breast Cancer.
  • MantaBio, creating a device used for microbial contamination detection in drug manufacturing to reduce the time for detection.
  • JoinedBio, creating a direct-to-patient marketplace that initially helps researchers get biospecimens from patients, and ultimately enables patients to manage access to their data, participate in clinical trials, etc.

Members reported on pending funding rounds, by Series number.

  • S96C – NF2Therapeutics,Inc.
  • S136 – NIRA
  • S137 – LenossMedical
  • S131 – PykusTherapeutics
  • S140 – AILean
  • S141 – GelMEDIX
  • S142 – iQ3Connect

April 8, 2025

AsparaGlue & Epivision

At the Beacon Angels meeting on April 8, 2025, we entertained new funding presentations as follows:

  • AsparaGlue, providing an elastic “superglue” surgical sealant to eliminate complications and aid recovery from major surgeries.
  • Epivision, developing an epigenetic liquid biopsy platform to improve the early detection, diagnosis, and monitoring of multiple cancer types.

We heard an update from Beacon portfolio company

  • Theromics, combining precision tumor ablation with intertumoral delivery of drugs and immunotherapies though a unique, patented hydrogel.

Members reported on companies in due diligence:

  • Iris Therapeutic Devices
  • Alpha Cure Therapeutics
  • Manta Bio

We considered multiple funding rounds, by Series number:

  • S136 – NIRA
  • S137 – LenossMedical
  • S141 – GelMEDIX

May 13, 2025

TherEx™ Medical Systems & WhisperSom

At the Beacon Angels meeting on May 13, 2025, we conducted the following business.

We entertained funding presentations from the following:

  • TherEx™MedicalSystems, developing novel products to advance skin and wound disinfection.
  • WhisperSom, non-invasive snoring and sleep apnea wearables.

We also heard a Beacon portfolio company update

  • Clearlaw, offering AI-driven software to analyze contracts and extract data at both the pre-execution phase for a single contract or across an entire repository of executed contracts.

Members reported on companies in due diligence:

  • IrisTherapeuticDevices
  • AlphaCureTherapeutics
  • MantaBio

We considered multiple funding rounds, by Series number:

  • S136 – NIRA
  • S137 – LenossMedical
  • S139 – Neosoma
  • S141 – GelMEDIX

June 10, 2025

Terrain Life Sciences & Make Cents

At the Beacon Angels meeting on June 10, 2025, we undertook the following activities:

We entertained new funding presentations as follows:

  • Terrain Life Sciences, AI-driven spatial proteomics for drug development, mapping protein targets at 10–100x greater depth, precision, and resolution.; and
  • MakeCents, a payments technology company offering privacy-first, ACH-based solutions for regulated and underserved merchants excluded by traditional processors.

We considered multiple funding rounds, by Series number:

  • S139 – Neosoma
  • S141 – GelMEDIX
  • S142 – Clearlaw
  • S143 – WhisperSom (recommended pass)
  • S144 – eCareVault

Members reported on companies in due diligence:

  • IrisTherapeuticDevices
  • MantaBio
  • WhisperSom (after IP review, recommended pass)

July 8, 2025

QSM Diagnostics, Reconstruct Bio & Aprive

Beacon Angels undertook the following at its meeting on July 8, 2025:

We entertained a follow-on funding proposal:

  • QSM Diagnostics, which is fundamentally changing how bacterial infections in pets are diagnosed and treated with easy-to-use, quick & accurate mail-in testing kits and proprietary in-clinic instruments using Quorum Sensing Technology.

We entertained new funding proposals:

  • Reconstruct Bio, which is transforming soft tissue restoration with personalized, living implants made from a patient’s own cells.
  • Aprive, which delivers discreet, concierge-level cybersecurity protection for high-profile individuals, executives, and family offices.

Members reported on companies in due diligence:

  • IRIS Therapeutic Devices, which is developing a device to treat and reverse the effects of Parkinson’s disease.
  • Terrain Life Sciences, which is developing AI-driven spatial proteomics mapping and analysis for more accurate drug development.

We discussed multiple funding rounds, by Series number:

  • S134 – eCare Vault (completed)
  • S139 – Neosoma (completed)
  • S141 – GelMEDIX (completed)
  • S143 – Clearlaw (in process)
  • S144 – MantaBio(in process).

September 9, 2025

Absentia Labs & Aleoop

At its meeting on September 9, 2025, Beacon Angels conducted the following business:

We entertained new funding presentations as follows:

  • Absentia Labs — creating an AI-powered platform for virtual, whole organism drug testing, assisting researchers to predict human outcomes from early animal models.
  • Aleoop — a B2B SaaS platform to help tech companies build products that sell by turning unstructured sales and support feedback into clear, actionable product signals.

We entertained a follow-on funding proposal:

  • GelMEDIX—Discussed current status and financing requirements.

Members reported on companies in due diligence:

  • IRIS Therapeutic Devices
  • Reconstruct Bio
  • Terrain Life Sciences

We discussed multiple funding rounds, by Series number:

  • S143 – Clearlaw (suspended)
  • S144- Manta Bio (completed)
  • S146 AOA Dx

October 14, 2025

Volute & Reflection Sciences

Beacon conducted the following business at its October 14, 2025 meeting:

We entertained new funding proposals from the following: 

  • Volute, using AI to enable top 100 business schools to become the world’s most powerful live workforce learning hub.
  • Reflection Sciences, helping educators, families, and students measure, and improve the executive function skills they need to succeed in school, career, and life.

We entertained a portfolio company update from:

  • RevBio, discussed current status and financing requirements.

Members reported on current funding rounds:

  • Series 147 – GelMEDIX
  • Series 149 – Agile Devices

Members reported on companies in due diligence:

  • IRIS Therapeutic Devices
  • Aleoop

November 11, 2025

Volute & Reflection Sciences

Beacon conducted the following business at its November 11, 2025 meeting:

We entertained new funding proposals from the following: 

  • whoo.ai, a Prop Tech startup at the intersection of voice-first conversational AI and physical infrastructure.
  • Akeyna, which produces novel blood vessel detection technology designed to deliver dermal fillers and drugs safely in cosmetic surgery.

We heard portfolio company updates from:

  • Lenoss Medical, fighting osteoporosis by restoring spinal fractures with natural bone. 
  • AmplifiDx, offering affordable, Rapid, and Accurate Point-of-Care Diagnostics for Family & Women’s Health.

Members reported on current funding rounds:

  • S113C – RevBio (pending)
  • S 139C – Neosoma (pending)
  • S 147 – GelMEDIX (closed)
  • S 149 – Agile Devices (closed)

Members reported on companies in due diligence:

  • ALEOOP
  • Reflection Sciences

December 9, 2025

MPWR & Endocure

Beacon conducted the following business at its December 9, 2025 meeting:

We entertained new funding proposals from the following: 

  • MPWR, a B2B fintech platform helping banks lend to 80M gig workers and 45M credit-invisible consumers by using proprietary agentic AI to build real-time, verified Credit IPs from financial behavior.
  • Endocure, which uses Revealan,™ a robotic ultrasound imaging platform to optimize ultrasound for better patient outcomes. Revealan integrates with off-the-shelf ultrasound devices to enable automated 10X higher-resolution 3D imaging than that of an MRI.

Members reported on closed, current and new funding rounds:

  • 113C – RevBio (closed)
  • 139C – Neosoma (closed)
  • 111C – AmplifiDx (awaiting pledges)
  • 150 – Lenoss (pending)

Members reported on companies in due diligence:

  • Akeyna
  • ALEOOP
  • Reflection Sciences

About Beacon Angels

Angel group, founded in 2006, that invests in early stage start-up companies--New England based only.
This entry was posted in Past Beacon Meetings and tagged , , , . Bookmark the permalink.